7+3	cytarabine (7 days) plus anthracycline (3 days)
ADCs	antibody–drug conjugates
ADCC	antibody-dependent cellular cytotoxicity
AE	adverse event
AKT	protein kinase B
ALFA-0701	Acute Leukemia French Association 0701 trial
allo-HSCT	allogeneic hematopoietic stem cell transplantation
ALT	alanine aminotransferase
AML	acute myeloid leukemia
APL	acute promyelocytic leukemia
ASH	American Society of Hematology
AST	aspartate aminotransferase
BAX	Bcl-2-associated X protein
BCL-2	B-cell lymphoma 2
BCL-XL	B-cell lymphoma-extra large
BIM	Bcl-2-interacting mediator of cell death
BM	bone marrow
CAR-T	chimeric antigen receptor T-cell therapy
CBC	complete blood count
CBF	core-binding factor
CD33	cluster of differentiation 33
CD34+	cluster of differentiation 34–positive cells
CD123	cluster of differentiation 123
CI	confidence interval
CLAD	cladribine-based regimen
CR	complete remission
CR1	first complete remission
CRc	composite complete remission
CRi	complete remission with incomplete hematologic recovery
CRp	complete remission with incomplete platelet recovery
CYP3A	cytochrome P450 3A
DFS	disease-free survival
DNA	deoxyribonucleic acid
ECG	electrocardiogram
ECHO	echocardiography
ECOG	Eastern Cooperative Oncology Group
EFS	event-free survival
ELN	European LeukemiaNet
ERK	extracellular signal-regulated kinase
Fab	fragment antigen-binding
Fc	fragment crystallizable
FDA	U.S. Food and Drug Administration
FLAG-IDA	fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin
FLT3	Fms-like tyrosine kinase 3
FLT3-ITD	Fms-like tyrosine kinase 3 internal tandem duplication
FLT3-TKD	Fms-like tyrosine kinase 3 tyrosine kinase domain mutation
G-CSF	granulocyte colony-stimulating factor
GO	gemtuzumab ozogamicin
HMA(s)	hypomethylating agent(s)
HR	hazard ratio
HSCT	hematopoietic stem cell transplantation
IDH(1/2)	isocitrate dehydrogenase (1/2)
ITD	internal tandem duplication
KIT	KIT proto-oncogene receptor tyrosine kinase
LDAC	low-dose cytarabine
LFTs	liver function tests
LSCs	leukemia stem cells
MCL-1	myeloid cell leukemia 1
MDS	myelodysplastic syndrome
MEK	Mitogen-activated protein kinase kinase
MRD	measurable residual disease
NCCN	National Comprehensive Cancer Network
NCT	ClinicalTrials.gov identifier
NGS	next-generation sequencing
NPM1	nucleophosmin 1
ORR	overall response rate
OS	overall survival
OXPHOS	oxidative phosphorylation
PFS	progression-free survival
PI3K	phosphoinositide 3-kinase
pSTAT5	phosphorylated signal transducer and activator of transcription 5
QALY(s)	quality-adjusted life year(s)
RADIUS	midostaurin maintenance trial
RAF	Rapidly accelerated fibrosarcoma kinase
RAS	rat sarcoma viral oncogene homolog
RATIFY	CALGB 10603 trial
RFS	relapse-free survival
RFT	renal function tests
R/R	relapsed/refractory
RR	relapse risk
SOS	sinusoidal obstruction syndrome
STAT5	signal transducer and activator of transcription 5
t(8;21)	translocation between chromosomes 8 and 21
TEAE	treatment-emergent adverse event
TKD	tyrosine kinase domain
TKI	tyrosine kinase inhibitor
TLS	tumor lysis syndrome
TP53	tumor protein p53
VEN	venetoclax
VIALE-A	venetoclax plus azacitidine trial
VIALE-C	venetoclax plus low-dose cytarabine trial
VOD	veno-occlusive disease
Y694(Tyr694)	Tyrosine residue at position 694